VIAGRA Drug Patent Profile

Which patents cover Viagra, and when can generic versions of Viagra launch?

Viagra is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viagra

A generic version of VIAGRA was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Summary for VIAGRA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	97
Clinical Trials:	165
Patent Applications:	7,242
Drug Prices:	Drug price information for VIAGRA
Drug Sales Revenues:	Drug sales revenues for VIAGRA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIAGRA
What excipients (inactive ingredients) are in VIAGRA?	VIAGRA excipients list
DailyMed Link:	VIAGRA at DailyMed

See drug prices for VIAGRA

See drug sales revenues for VIAGRA

Recent Clinical Trials for VIAGRA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bio-innova Co., Ltd	PHASE1
Aspargo Labs, Inc	PHASE1
University Hospital, Rouen	Phase 3

See all VIAGRA clinical trials

Pharmacology for VIAGRA

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for VIAGRA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIAGRA	Tablets	sildenafil citrate	25 mg and 50 mg	020895	1	2004-11-19
VIAGRA	Tablets	sildenafil citrate	100 mg	020895	1	2004-10-25

US Patents and Regulatory Information for VIAGRA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-001	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-002	Mar 27, 1998	AB	RX	Yes	No
Viatris	VIAGRA	sildenafil citrate	TABLET;ORAL	020895-003	Mar 27, 1998	AB	RX	Yes	Yes

International Patents for VIAGRA

See the table below for patents covering VIAGRA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	121403
Australia	626757
Australia	7915591
Brazil	9102560

Supplementary Protection Certificates for VIAGRA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	300048	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0463756	SPC/GB99/004	United Kingdom		PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756	99C0007	Belgium		PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622

Viagra (sildenafil) Market Dynamics and Financial Trajectory: Pricing, Share, Exclusivity, Generics, and Revenue Outlook

Last updated: July 24, 2026

Viagra’s financial trajectory is structurally capped by long-running generic availability in the US and Europe, shifting the market from patent-driven premium pricing to branded share protection via distribution, contracting, patient/physician familiarity, and distinct lifecycle assets (formulations, dosing convenience, and patient support). In practice, branded revenue has stabilized but contracted over time as generics expanded and payers tightened reimbursement.

---

How big is the Viagra market and who buys it?

Answer: Viagra is a large, mature PDE5-inhibitor category where branded share is defended rather than expanded. Demand is driven by aging demographics, stable underlying ED prevalence, and the category’s substitution across sildenafil, tadalafil, vardenafil, and avanafil.

US demand drivers

Key market forces shaping unit and dollar performance:

• Payer substitution: Formularies increasingly favor low-cost generics and therapeutically equivalent alternatives.
• Low switching friction: Sildenafil is widely interchangeable by dose form and patient response.
• Channel mix: Retail pharmacy remains the primary setting for prescriptions; online and mail order influence net price through volume rebates.

International demand drivers

• Regulatory and pricing controls: EU member-state reimbursement policies typically accelerate generic share gains.
• Parallel trade: In some jurisdictions, cross-border supply affects effective pricing and net revenue.

---

What is Viagra’s revenue trajectory versus key competitors (Cialis/others)?

Answer: Viagra’s branded sales track the broader PDE5-inhibitor category but run below newer, still-monetizing branded competitors like tadalafil-focused products in periods where those competitors have stronger payer positioning.

Category substitution mechanics

PDE5 inhibitors are therapeutic substitutes with similar clinician and patient decision pathways:

• Patients trade off onset speed and duration (tadalafil tends to win “longer window” perceptions; sildenafil is often positioned on dosing flexibility and familiarity).
• Payers trade off acquisition cost and contracted branded discounts versus generic benchmarks.

Competitive set

• Cialis (tadalafil): often commands pricing power when branded contracting holds, especially where prescribers prefer “longer duration.”
• Levitra (vardenafil) and Stendra (avanafil): typically smaller shares, with localized competitive dynamics.

---

How do generic erosion and price indexing affect Viagra profitability?

Answer: Generic entry forces a steep decline in branded net price and increases marketing and contracting costs as brand owners defend share.

Financial mechanics of erosion

• Net price compression: Even when branded supply persists, payers increasingly require higher patient cost-sharing for branded sildenafil.
• Rebate economics: Branded revenue can remain stable in gross terms while net profit shifts due to higher contracting and promotional spend.
• Mix shift to lower-cost channels: As generics increase, residual branded demand skews toward patients with effective copay assistance or prescriber preference for a particular dosing regimen.

What typically happens to branded unit share

• Unit share often declines first in formularies that list generics as preferred.
• Brand owners can slow erosion through:
  • co-pay programs (where legally available and operationally consistent),
  • contracting that maintains inclusion for at least one dose/pack size,
  • and patient support that lowers out-of-pocket barriers.

---

What patents protect Viagra and when does exclusivity end?

Answer: Viagra’s core active ingredient sildenafil is long off patent in most major markets; the remaining IP value is typically confined to later-life cycle patents (specific formulations, dosing regimens, packaging, and manufacturing methods) rather than fundamental composition-of-matter protection.

US exclusivity and patent posture

• Sildenafil’s origin IP is expired; post-expiration protection is usually limited to:
  • specific dosage form innovations (where pursued),
  • and certain manufacturing/process claims.

Europe and rest of world

• EU and other high-income markets follow similar patterns: composition and early-use claims have expired; residual patent fences are typically narrow.

---

What generic entry risks exist for Viagra in the US and EU?

Answer: The principal risk is no longer Paragraph IV-driven composition entry because sildenafil generics are already established. Ongoing risk is incremental: additional abbreviated-approval entrants, price undercutting, and substitution into preferred-tier formularies.

US regulatory pathway reality

• Existing sildenafil generics reduce the probability that new regulatory events will materially change category economics.
• The key risk is commercial: payers renegotiate to prefer the lowest-cost suppliers.

Manufacturing/IP barriers

• Barriers shift from patent infringement risk to:
  • bioequivalence readiness,
  • supply reliability,
  • and ability to meet payer contracting and pharmacovigilance expectations.

---

What is the Orange Book status of Viagra?

Answer: Viagra’s Orange Book-linked protected drug approvals include the original NDA listing and any later manufacturing or formulation-related patents still recorded. However, the composition-level exclusivities are expired; remaining listings, where present, usually cover narrow claims and do not prevent generic sildenafil widespread access.

Featured snippet: Orange Book implications

• Orange Book listings do not support a sustained, broad market monopoly for sildenafil.
• Market dynamics are dominated by generic availability and contracting rather than legal exclusivity.

---

How do formulation and delivery-system patents affect long-term pricing?

Answer: Formulation patents can sustain branded relevance by supporting dosing convenience, patient adherence, and physician familiarity, but they do not reverse generic reference pricing.

Practical impact

• A branded formulation that improves adherence can modestly slow brand unit share erosion.
• Still, if generics offer equivalent strength and dosing, payer cost minimization typically overrides brand preference.

---

What financial metrics best explain Viagra’s trajectory (net sales, operating margin, marketing spend)?

Answer: For a mature generic-competitive branded drug, the most predictive metrics are:

• net sales (and the net-to-gross ratio via rebates),
• operating income and margin under sustained promotional spend,
• and annual prescription volumes (where disclosed by company or analytics providers).

What to watch in annual reporting

• Gross-to-net compression trend: indicates payer pressure and rebate intensity.
• SG&A ratio: signals the cost of defending residual branded share.
• Gross margin resilience: can persist if the brand remains on favorable manufacturing economics and packaging scale.

---

How does contract pricing with PBMs shape Viagra net revenue?

Answer: PBM contracts determine whether branded sildenafil remains included in preferred tiers or pushed to higher-cost tiers.

Key levers

• preferred formulary placement for selected brands or pack sizes,
• value-based rebates tied to volume or persistence,
• patient assistance programs that offset copay burdens.

Outcome

• When PBMs widen generic preferred listing, branded net revenue declines even if branded prescriptions remain visible.

---

What litigation or settlement activity matters for Viagra today?

Answer: The major-era patent battles for sildenafil are largely past; ongoing litigation risk is usually limited to incremental formulation/manufacturing claims, labeling disputes, or enforcement around specific product presentations.

Why settlement terms rarely change category economics

• With composition broadly generic, settlements tend to be commercial and presentation-specific rather than re-establishing exclusivity.

---

How does Viagra’s financial trajectory compare with “new entry” ED drugs?

Answer: Newer branded ED products can experience higher pricing power during periods where payer contracting supports brand differentiation. Viagra’s trajectory is structurally more dependent on:

• residual brand loyalty,
• contracting execution,
• and cost-controlled supply.

Competitive comparison in one line

• Viagra: mature, generic-dominant pricing environment; revenue depends on net contracting outcomes.
• Newer entrants: more room for price discipline during brand exclusivity phases.

---

Where does revenue risk concentrate: US vs EU vs emerging markets?

Answer: Revenue risk concentrates in the region where generic penetration and payer formulary strictness are highest.

US risk profile

• Formularies often favor generics; branded survival depends on contract position and patient access programs.

EU risk profile

• Generic availability and health system reimbursement constraints typically accelerate branded contraction.

Emerging markets

• More variable: the trajectory depends on:
  • regulatory speed for generic approvals,
  • local enforcement of branded supply,
  • and affordability pressures.

---

What is the most likely commercial scenario for Viagra over the next 3 to 5 years?

Answer: Expect continued brand share defense without renewed premium pricing. Net revenue is likely to remain constrained by:

• continued substitution,
• contract renegotiations,
• and ongoing generic price competition.

Scenario structure

• Base case: branded unit declines slowly; net sales drift down or flatten depending on contracting.
• Downside: tiering worsens and patient assistance pressure rises; net revenue declines faster.
• Upside: improved pack/formulation competitiveness and stable payer contracting maintain share.

---

Key Takeaways

• Viagra is a mature, generic-dominant market where branded financial performance depends on net pricing, rebate economics, and payer placement rather than patent exclusivity.
• Generic erosion compresses branded net price and shifts profitability to rebate management and SG&A efficiency.
• Orange Book status does not support broad exclusivity; residual IP, where present, typically covers narrow presentations and does not block category substitution.
• The near-term trajectory is dominated by PBM contracting outcomes and continued payer preference for lowest-cost sildenafil or therapeutically equivalent alternatives.

---

FAQs

1. How do PBM formulary changes typically impact Viagra net sales within a year?
   They usually drive fast declines in branded net sales through tiering, higher patient cost-sharing, and reduced preferred placement for branded sildenafil pack sizes.

2. Do sildenafil generics and brand Viagra compete on onset speed or duration?
   In practice, competition is more payer- and cost-driven because generics match strength and dosing instructions; clinical differentiation usually doesn’t sustain a premium against strong generic pricing.

3. Are there biosimilar-like dynamics for ED drugs that could threaten sildenafil’s category stability?
   No. PDE5 inhibitors are small molecules with generic frameworks, not biologics; competitive dynamics follow generic substitution and contracting.

4. Which product attributes most influence physician prescribing persistence for Viagra?
   Dosing convenience, perceived tolerability, patient history, and formulary accessibility for specific sildenafil strengths/pack sizes.

5. Can later-life-cycle sildenafil formulations materially extend branded revenue?
   They can slow erosion by supporting adherence and maintaining some formulary inclusion, but they rarely reverse generic-driven price compression.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-24).
2. FDA. Drugs@FDA: Viagra (sildenafil) and associated approvals (Accessed 2026-07-24).

DrugChatter Q&A for VIAGRA

Viagra patent expiration date?
When did the paton expire on viagra?
How much money does viagra make a year?
When does viagra patent end?
Viagra patent expiration wiki?